Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.67 |
| ▸ | F2 | P00734 | 4/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4687014 | 0.85 | F10 (0.65) | F10F2NPC1 | |
| Trifluoroacetic Acid SCHEMBL4687033 | 0.83 | F10 (0.46) | F10F2F3 | |
| Trifluoroacetic Acid SCHEMBL3897265 | 0.82 | F10 (0.75) | F10F2NPC1F3 | |
| Trifluoroacetic Acid SCHEMBL4687003 | 0.82 | F10 (0.64) | F10F2NPC1F3 | |
| SCHEMBL14132315 | 0.81 | F10 (1.00) | F10F2NPC1 | |
| Trifluoroacetic Acid SCHEMBL3899621 | 0.80 | F10 (0.75) | F10F2NPC1F3 | |
| Trifluoroacetic Acid SCHEMBL3905842 | 0.80 | F10 (0.72) | F10F2NPC1F3 | |
| Trifluoroacetic Acid SCHEMBL3905673 | 0.78 | F10 (0.92) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL3902136 | 0.78 | F10 (0.74) | F10F2 | |
| SCHEMBL14132135 | 0.77 | F10 (0.83) | F10F2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | F10 26/4885F2 2/4885MCHR1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.